Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children

STATUS

Recruiting
End date

Dec 22, 2023
participants needed

400
sponsor

Xiamen Amoytop Biotech Co., Ltd.

Send

Updated on 22 March 2022

See if I qualify

somatomedin c

stimulation test

somatropin

short stature

Summary

This is a multicenter, randomized, open-labeled, positive controlled phase 2&3 combined study to evaluate the safety and efficacy of weekly Y-shape pegylated somatropin, compared to daily somatropin (Norditropin®), in prepubertal, treatment-naive children with growth hormone deficiency.

Description

This multicenter, randomized, open-labeled, positive controlled study is divided into two stages. The first one is aimed to exploit the optimal dose of Y-shape pegylated somatropin, while the second one is aimed to confirm the efficacy and safety of the study drug. A total of 400 prepubertal children with growth hormone deficiency were expected to enrolled. Subjects will firstly undergo a 52 weeks treatment, and then followed for 5 weeks.

Details

Condition	Growth Hormone Deficiency
Treatment	Norditropin, Norditropin®, Y-shape pegylated somatropin
Clinical Study Identifier	NCT04513171
Sponsor	Xiamen Amoytop Biotech Co., Ltd.
Last Modified on	22 March 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Diagnosis of GHD confirmed by two different GH stimulation tests, defined as a peak of GH level of <10.0 ng/ml, determined with a validated assay. Bone age (BA) at least 2 years less than the chronological age. Growth velocity less than 5.0 cm/year. Impaired HT defined as at least 2.0 standard deviations (SD) below of the mean height for chronological age and sex (HT SDS<-2.0)
	Prepubertal (Tanner Ⅰ) males and females by physical examination, aged older than 3 years and younger than10 years for girls and 11 years for boys
	Short stature with normal intelligence
	Baseline IGF-1 level below the median IGF-1 level standardized for age and sex
	Written, signed informed consent of the parent(s) or legal guardian(s) of the subject and written assent of the subject (if the subject is 8 years old or above)
Exclusion Criteria
	Prior exposure to growth promotion treatment, such as recombinant human growth hormone or gonadal hormones, for more than 1 month
	Known hypersensitivity to somatropin or excipients, such as mannitol, lysine, sodium chloride
	Children with closed epiphyses
	Short stature etiologies other than GHD, such as idiopathic short stature, Turner syndrome, Prader-Willi syndrome, Russell-Silver syndrome, born small for gestational age regardless of GH status
	Other causes of short stature such as hypothyroidism, adrenocortical hormone deficiency, antidiuretic hormone deficiency
	Any medical conditions and/or presence that may affect growth velocity such as liver dysfunction, kidney dysfunction, malnutrition, diabetes mellitus, severe dysfunction in major organ such as heart, sever systemic infections, severe immune dysfunction, mental disorders, and other congenital malformations
	Suffering from chronic infectious diseases such as chronic hepatitis B, AIDS or tuberculosis
	Receiving non-physiological adrenal corticosteroids
	Confirmed pituitary and/or hypothalamic malignance by MRI within one year prior to screening. History or presence of any other malignance disease, any evidence of present tumor growth
	Evidence of congenital intracranial hypertension
	Evidence of slipped capital femoral epiphysis
	Evidence of scoliosis over 15°
	Participation in any other trial of an investigational agent within 3 months prior to screening
	Any other conditions which in the opinion of the investigator precluded enrollment into the study

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children